ジフテリア:治療薬開発パイプライン分析

Global Markets Directが発行した調査報告書(GMDHC9887IDB)
◆英語タイトル:Diphtheria - Pipeline Review, H2 2017
◆商品コード:GMDHC9887IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年11月14日
◆ページ数:65
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界におけるジフテリアの治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・ジフテリアの概要
・ジフテリア治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・ジフテリアパイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・ジフテリア治療薬開発に取り組んでいる企業:企業別製品パイプライン
・ジフテリア治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Diphtheria – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Diphtheria – Pipeline Review, H2 2017, provides an overview of the Diphtheria (Infectious Disease) pipeline landscape.

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Diphtheria – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diphtheria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diphtheria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 8, 4, 4, 1 and 6 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 2 molecules, respectively.

Diphtheria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diphtheria (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Diphtheria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diphtheria (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diphtheria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diphtheria (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diphtheria (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diphtheria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diphtheria – Overview 8
Diphtheria – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Diphtheria – Therapeutics Assessment 15
Assessment by Target 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Diphtheria – Companies Involved in Therapeutics Development 21
Beijing Minhai Biotechnology Co Ltd 21
Biological E Ltd 21
Cadila Healthcare Ltd 21
Daiichi Sankyo Co Ltd 22
GlaxoSmithKline Plc 22
Green Cross Corp 23
Indian Immunologicals Ltd 24
Kaketsuken 24
LG Chem Ltd 24
Sanofi 25
Sanofi Pasteur SA 25
Serum Institute of India Ltd 26
Shantha Biotechnics Pvt Ltd 26
Diphtheria – Drug Profiles 28
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine – Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine – Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine – Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine – Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine – Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine – Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine – Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
(diphtheria + pertussis (acellular) + tetanus) vaccine 1 – Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 – Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
(diphtheria + pertussis (whole cell) + tetanus) (trivalent) vaccine – Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
(diphtheria + pertussis (whole cell) + tetanus) vaccine – Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
(diphtheria + pertussis (whole-cell) + tetanus) vaccine – Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine – Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
(diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine – Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
(diphtheria + tetanus + pertussis (acellular)) vaccine – Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine – Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine – Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
BK-1310 – Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
DTaP-IPV-HB-PRPT – Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
GC-3111A – Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
KD-370 – Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
LBVD – Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
VN-0105 – Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Diphtheria – Dormant Projects 58
Diphtheria – Discontinued Products 61
Diphtheria – Product Development Milestones 62
Featured News & Press Releases 62
Mar 17, 2015: Sanofi: Shantha Will Provide Up To 37 Million Doses Of Shan5 62
Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA 62
Nov 10, 2014: Shantha’s Pentavalent Pediatric Vaccine launched in India 62
May 05, 2014: Shantha’s Pentavalent Pediatric Vaccine prequalified by World Health Organization 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65

List of Tables
Number of Products under Development for Diphtheria, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Number of Products under Development by Universities/Institutes, H2 2017 11
Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13
Products under Development by Universities/Institutes, H2 2017 14
Number of Products by Stage and Target, H2 2017 16
Number of Products by Stage and Route of Administration, H2 2017 18
Number of Products by Stage and Molecule Type, H2 2017 20
Diphtheria - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017 21
Diphtheria - Pipeline by Biological E Ltd, H2 2017 21
Diphtheria - Pipeline by Cadila Healthcare Ltd, H2 2017 22
Diphtheria - Pipeline by Daiichi Sankyo Co Ltd, H2 2017 22
Diphtheria - Pipeline by GlaxoSmithKline Plc, H2 2017 23
Diphtheria - Pipeline by Green Cross Corp, H2 2017 23
Diphtheria - Pipeline by Indian Immunologicals Ltd, H2 2017 24
Diphtheria - Pipeline by Kaketsuken, H2 2017 24
Diphtheria - Pipeline by LG Chem Ltd, H2 2017 25
Diphtheria - Pipeline by Sanofi, H2 2017 25
Diphtheria - Pipeline by Sanofi Pasteur SA, H2 2017 26
Diphtheria - Pipeline by Serum Institute of India Ltd, H2 2017 26
Diphtheria - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2017 27
Diphtheria - Dormant Projects, H2 2017 58
Diphtheria - Dormant Projects, H2 2017 (Contd..1), H2 2017 60
Diphtheria - Discontinued Products, H2 2017 61

List of Figures
Number of Products under Development for Diphtheria, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Number of Products under Development by Universities/Institutes, H2 2017 11
Number of Products by Targets, H2 2017 15
Number of Products by Stage and Targets, H2 2017 15
Number of Products by Routes of Administration, H2 2017 17
Number of Products by Stage and Routes of Administration, H2 2017 17
Number of Products by Molecule Types, H2 2017 19
Number of Products by Stage and Molecule Types, H2 2017 19

【レポートのキーワード】

ジフテリア

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ジフテリア:治療薬開発パイプライン分析(Diphtheria - Pipeline Review, H2 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆